首页> 外文期刊>Cureus. >Fractional Exhaled Nitric Oxide Testing: Diagnostic Utility in Asthma, Chronic Obstructive Pulmonary Disease, or Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome
【24h】

Fractional Exhaled Nitric Oxide Testing: Diagnostic Utility in Asthma, Chronic Obstructive Pulmonary Disease, or Asthma-chronic Obstructive Pulmonary Disease Overlap Syndrome

机译:呼出气一氧化氮检测:对哮喘,慢性阻塞性肺疾病或哮喘慢性阻塞性肺疾病重叠综合征的诊断作用

获取原文
       

摘要

Asthma and chronic obstructive pulmonary disease (COPD) can present as unique conditions or as a combination known as asthma-chronic obstructive pulmonary disease?overlap syndrome (ACOS). These condition(s) can be categorized as obstructive conditions, causing inflammation of small airways leading to decrease airflow, mucus production, and bronchoconstriction. Asthma and COPD affect every age, gender, ethnicity, and socioeconomic status, thus increasing mortality and morbidity burden in our society. Fractional exhaled nitric oxide (FeNO) is an endogenous gaseous molecule which can be measured in the human breath test because of airway inflammation. It has been studied extensively as a marker of inflammation and has been incorporated into an algorithm for asthma management. The purpose of this study was to investigate whether FeNO?testing can lead to a change in the diagnosis. A retrospective chart review of 95 patients with asthma, COPD, and ACOS was performed, and FeNO levels were recorded. Out of 95 patients, 36%, 24%, and 22% of the patients had an initial diagnosis of asthma, COPD, and ACOS, respectively. After the FeNO testing, the number of patients with the final diagnosis of asthma and ACOS increased, and COPD decreased. Our results support the utility of FeNO as a viable marker in diagnosing and managing complex cases of asthma, COPD, and ACOS.
机译:哮喘和慢性阻塞性肺疾病(COPD)可以表现为独特的病症,也可以称为哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)。这些疾病可以归为阻塞性疾病,引起小气道发炎,导致气流减少,粘液产生和支气管收缩。哮喘和慢性阻塞性肺病会影响每个年龄,性别,种族和社会经济地位,从而增加我们社会的死亡率和发病率负担。呼出气一氧化氮(FeNO)是一种内源性气态分子,由于气道发炎,可以在人的呼气试验中进行测量。它已被广泛研究作为炎症的标志物,并已被纳入哮喘治疗的算法中。这项研究的目的是调查FeNO3检测是否可以导致诊断改变。回顾性分析了95例哮喘,COPD和ACOS患者的病历,并记录了FeNO水平。在95位患者中,分别有36%,24%和22%的患者对哮喘,COPD和ACOS进行了初步诊断。经过FeNO测试后,能够​​最终诊断出哮喘和ACOS的患者人数有所增加,而COPD有所减少。我们的研究结果支持了FeNO在诊断和处理哮喘,COPD和ACOS复杂病例中的可行性标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号